COMP <GO>
PFE vs MRK // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Pfizer Inc. (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: PFE 3
— MRK 11
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: MRK
LAST: $30.52 (+1.90%) • MKT CAP: $170.71B
options-implied-move
7.10%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
options-implied-move
6.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PFE VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PFE | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.30% | 74.80% | -0.50 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 5.10% | 20.70% | -15.60 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.7x | 15.3x | +4.40 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 5.32% | 3.42% | +1.90 | PFE | /fcf-yield <GO> |
| Operating Margin | 15.10% | 34.30% | -19.20 | MRK | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 28.10% | -15.70 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -1.60% | 1.30% | -2.90 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.10 | 5.19 | -3.09 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 7.10% | 6.60% | +0.50 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.5 | 56.9 | +9.68 | PFE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 0.92 | +0.13 | PFE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.5x | 18.4x | +2.10 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $170.71B | $361.02B | -$190.32B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PFE REV | MRK REV | PFE GROSS % | MRK GROSS % | PFE FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $62.58B | $65.01B | 74.3% | 74.8% | $9.07B | $12.36B |
| FY 2024 | $63.63B | $64.17B | 71.9% | 76.3% | $9.84B | $18.10B |
| FY 2023 | $50.91B | $60.12B | 44.0% | 44.0% | $6.41B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PFE // BETA 1.05
MRK // BETA 0.92